От тела к мозгу. Как нарушения метаболизма становятся причиной депрессии, биполярного расстройства, СДВГ, ПТСР и других заболеваний - Кристофер М. Палмер

Daniels, P. Brown, et al. “Mitochondrial Reactive Oxygen Species Regulate the Strength of Inhibitory GABA-Mediated Synaptic Transmission.” Nat Commun 5 (2014): 3168. doi: 10.1038/ ncomms4168.

4. A. K. Kanellopoulos, V. Mariano, M. Spinazzi, Y. J. Woo, C. McLean, U. Pech, K. W. Li, J. D. Armstrong, A. Giangrande, P. Callaerts, A. B. Smit, B. S. Abrahams, A. Fiala, T. Achsel, and C. Bagni. “Aralar Sequesters GABA into Hyperactive Mitochondria, Causing Social Behavior Deficits.” Cell 180(6) (March 19, 2020): 1178–1197.e20. doi: 10.1016/j.cell.2020.02.044.

5. Ryutaro Ikegami, Ippei Shimizu, Takeshi Sato, Yohko Yoshida, Yuka Hayashi, Masayoshi Suda, Goro Katsuumi, et al. “Gamma-Aminobutyric Acid Signaling in Brown Adipose Tissue Promotes Systemic Metabolic Derangement in Obesity.” Cell Rep 24(11) (2018): 2827–2837.e5. doi: 10.1016/j.celrep.2018.08.024.

6. S. M. Graves, Z. Xie, K. A. Stout, et al. “Dopamine Metabolism by a Monoamine Oxidase Mitochondrial Shuttle Activates the Electron Transport Chain.” Nat Neurosci 23 (2020): 15–20.

7. D. Aslanoglou, S. Bertera, M. Sánchez-Soto, et al. “Dopamine Regulates Pancreatic Glucagon and Insulin Secretion via Adrenergic and Dopaminergic Receptors.” Transl Psychiatry 11(1) (2021): 59. doi: 10.1038/ s41398-020-01171-z.

8. M. van der Kooij, F. Hollis, L. Lozano, et al. “Diazepam Actions in the VTA Enhance Social Dominance and Mitochondrial Function in the Nucleus Accumbens by Activation of Dopamine D1 Receptors.” Mol Psychiatry 23(3) (2018): 569–578. doi: 10.1038/mp.2017.135.

9. M. van der Kooij, et al. “Diazepam Actions in the VTA Enhance Social Dominance and Mitochondrial Function in the Nucleus Accumbens by Activation of Dopamine D1 Receptors.»

10. T. L. Emmerzaal, G. Nijkamp, M. Veldic, S. Rahman, A. C. Andreazza, E. Morava, R. J. Rodenburg, and T. Kozicz. “Effect of Neuropsychiatric Medications on Mitochondrial Function: For Better or for Worse.” Neurosci Biobehav 127 (Rev. August 2021): 555–571. doi: 10.1016/j.neubiorev.2021.05.001.

11. Martin Lundberg, Vincent Millischer, Lena Backlund, Lina Martinsson, Peter Stenvinkel, Carl M. Sellgren, Catharina Lavebratt, and Martin Schalling. “Lithium and the Interplay Between Telomeres and Mitochondria in Bipolar Disorder.” Front Psychiatry 11 (2020): 997. doi: 10.3389/fpsyt.2020.586083.

12. M. Hu, R. Wang, X. Chen, M. Zheng, P. Zheng, Z. Boz, R. Tang, K. Zheng, Y. Yu, and X. F. Huang. “Resveratrol Prevents Haloperidol-Induced Mitochondria Dysfunction Through the Induction of Autophagy in SH-SY5Y Cells.” Neurotoxicology 87 (2021): 231–242. doi: 10.1016/j.neuro.2021.10.007.

13. D. C. Goff, G. Tsai, M. F. Beal, and J. T. Coyle. “Tardive Dyskinesia and Substrates of Energy Metabolism in CSF.” Am J Psychiatry 152(12) (1995): 1730–6. doi: 10.1176/ajp.152.12.1730. PMID: 8526238.

14. M. Salsaa, B.Pereira, J. Liu, et al. “Valproate Inhibits Mitochondrial Bioenergetics and Increases Glycolysis in Saccharomyces cerevisiae.” Sci Rep 10(1) (2020): 11785. doi: 10.1038/s41598-020-68725-5.

15. J. F. Hayes, A. Lundin, S. Wicks, G. Lewis, I. C. K. Wong, D. P. J. Osborn, and C. Dalman. “Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides with Rates of Psychiatric Hospitalization and Self-Harm in Individuals with Serious Mental Illness.” JAMA Psychiatry 76(4) (2019): 382–390. doi: 10.1001/jamapsychiatry.2018.3907.

16. S. Martín-Rodríguez, P. de Pablos-Velasco, and J. A. L. Calbet. “Mitochondrial Complex I Inhibition by Metformin: Drug-Exercise Interactions.” Trends Endocrinol Metab 31(4) (April 2020): 269–271. doi: 10.1016/j.tem.2020.02.003.

Глава 12

1. P. Maechler. “Mitochondrial Function and Insulin Secretion.” Mol Cell Endocrinol 379(1–2) (2013): 12–18. doi: 10.1016/j.mce.2013. 06.019.

2. W. I. Sivitz and M. A. Yorek. “Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities.” Antioxid Redox Signal 12(4) (2010): 537–577. doi: 10.1089/ars.2009.2531.

3. C. S. Stump, K. R. Short, M. L. Bigelow, J. M. Schimke, and K. S. Nair. “Effect of Insulin on Human Skeletal Muscle Mitochondrial ATP Production, Protein Synthesis, and mRNA Transcripts.” Proc Natl Acad Sci USA 100(13) (2003): 7996–8001. doi: 10.1073/pnas.1332551100.

4. A. Kleinridders, H. A. Ferris, W. Cai, and C. R. Kahn. “Insulin Action in Brain Regulates Systemic Metabolism and Brain Function.” Diabetes 63(7) (2014): 2232–2243. doi: 10.2337/db14-0568.

5. E. Blázquez, E. Velázquez, V. Hurtado-Carneiro, and J. M. Ruiz-Albusac. “Insulin in the Brain: Its Pathophysiological Implications for States Related with Central Insulin Resistance, Type 2 Diabetes and Alzheimer’s Disease.” Front Endocrinol (Lausanne) 5 (2014): 161. doi: 10.3389/fendo.2014.00161.

6. Z. Jin, Y. Jin, S. Kumar-Mendu, E. Degerman, L. Groop, and B. Birnir. “Insulin Reduces Neuronal Excitability by Turning on GABA(A) Channels That Generate Tonic Current.” PLoS One 6(1) (2011): e16188. doi: 10.1371/journal.pone.0016188.

7. Ismael González-García, Tim Gruber, and Cristina García-Cáceres. “Insulin Action on Astrocytes: From Energy Homeostasis to Behaviour.” J Neuroendocrinol 33(4) (2021): e12953. doi: 10.1111/jne.12953.

8. A. Kleinridders, W. Cai, L. Cappellucci, A. Ghazarian, W. R. Collins, S. G. Vienberg, E. N. Pothos, and C. R. Kahn. “Insulin Resistance in Brain Alters Dopamine Turnover and Causes Behavioral Disorders.” Proc Natl Acad Sci USA 112(11) (2015): 3463–3468. doi: 10.1073/pnas.1500877112.

9. Virginie-Anne Chouinard, David C. Henderson, Chiara Dalla Man, Linda Valeri, Brianna E. Gray, Kyle P. Ryan, Aaron M. Cypess, Claudio Cobelli, Bruce M. Cohen, and Dost Öngür. “Impaired Insulin Signaling in Unaffected Siblings and Patients with First-Episode Psychosis.” Mol Psychiatry 24 (2018). doi: 10.1038/ s41380-018-0045-1.

10. B. I. Perry, J. Stochl, R. Upthegrove, et al. “Longitudinal Trends in Childhood Insulin Levels and Body Mass Index and Associations with Risks of Psychosis and Depression in Young Adults.” JAMA Psychiatry 78(4) (2021): 416–425. doi: 10.1001/jamapsychiatry.2020.4180.

11. B. J. Neth and S. Craft. “Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages. Front Aging Neurosci 9 (2017): 345. doi: 10.3389/fnagi.2017.00345; Y. An, V. R. Varma, S. Varma, R. Casanova, E. Dammer, O. Pletnikova, C. W. Chia, J. M. Egan, L. Ferrucci, J. Troncoso, A. I. Levey, J. Lah, N. T. Seyfried, C. Legido-Quigley, R. O’Brien, and M. Thambisetty. “Evidence for Brain Glucose Dysregulation in Alzheimer’s Disease.” Alzheimers Dement 14(3) (2018): 318–329. doi: 10.1016/j.jalz.2017.09.011.

12. S. Craft, L. D. Baker, T. J. Montine, et al. “Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment: A Pilot Clinical Trial.” Arch Neurol 69(1) (2012): 29–38. doi: 10.1001/ archneurol.2011.233.

13. S. Craft, R. Raman, T. W. Chow, et al. “Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial.” JAMA Neurol 77(9) (2020): 1099–1109. doi: 10.1001/jamaneurol.2020.1840.

14. R. S. McIntyre, J. K. Soczynska, H. O. Woldeyohannes, A. Miranda, A. Vaccarino, G. Macqueen, G. F. Lewis, and S. H. Kennedy. “A Randomized, Double-Blind, Controlled Trial Evaluating the Effect of Intranasal